Foghorn Therapeutics Inc. financial statements
Foghorn Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
FY2025
| Revenue | USD 30.91M | 10-K |
| Net income | −USD 74.28M | 10-K |
| Cash and equivalents | USD 80.88M | 10-Q |
| Total debt | USD 41.27M | EODHD |
Foghorn Therapeutics Inc. financials on 6ix · Foghorn Therapeutics Inc. on 6ix